101 related articles for article (PubMed ID: 15928261)
1. Medication associated with weight gain may influence outcome in a weight management program.
Malone M; Alger-Mayer SA; Anderson DA
Ann Pharmacother; 2005; 39(7-8):1204-8. PubMed ID: 15928261
[TBL] [Abstract][Full Text] [Related]
2. The lifestyle challenge program: a multidisciplinary approach to weight management.
Malone M; Alger-Mayer SA; Anderson DA
Ann Pharmacother; 2005 Dec; 39(12):2015-20. PubMed ID: 16288070
[TBL] [Abstract][Full Text] [Related]
3. Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women.
Collins RW; Anderson JW
Prev Med; 1995 Jul; 24(4):369-74. PubMed ID: 7479627
[TBL] [Abstract][Full Text] [Related]
4. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
[TBL] [Abstract][Full Text] [Related]
5. Weight loss in overweight patients maintained on atypical antipsychotic agents.
Centorrino F; Wurtman JJ; Duca KA; Fellman VH; Fogarty KV; Berry JM; Guay DM; Romeling M; Kidwell J; Cincotta SL; Baldessarini RJ
Int J Obes (Lond); 2006 Jun; 30(6):1011-6. PubMed ID: 16432547
[TBL] [Abstract][Full Text] [Related]
6. Effects of an educational intervention on weight gain in patients treated with antipsychotics.
Mauri M; Castrogiovanni S; Simoncini M; Iovieno N; Miniati M; Rossi A; Dell'Agnello G; Fagiolini A; Donda P; Cassano GB
J Clin Psychopharmacol; 2006 Oct; 26(5):462-6. PubMed ID: 16974185
[TBL] [Abstract][Full Text] [Related]
7. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
[TBL] [Abstract][Full Text] [Related]
8. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
9. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
Chen CK; Chen YC; Huang YS
Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
[TBL] [Abstract][Full Text] [Related]
10. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
11. High body mass index and posttransplant weight gain are not risk factors for kidney graft and patient outcome.
Marcén R; Fernández A; Pascual J; Teruel JL; Villafruela JJ; Rodriguez N; Martins J; Burgos FJ; Ortuño J
Transplant Proc; 2007 Sep; 39(7):2205-7. PubMed ID: 17889138
[TBL] [Abstract][Full Text] [Related]
12. Weight loss strategies for obese adults: personalized weight management program vs. standard care.
Byrne NM; Meerkin JD; Laukkanen R; Ross R; Fogelholm M; Hills AP
Obesity (Silver Spring); 2006 Oct; 14(10):1777-88. PubMed ID: 17062808
[TBL] [Abstract][Full Text] [Related]
13. Insulin treatment and the problem of weight gain in type 2 diabetes.
Carver C
Diabetes Educ; 2006; 32(6):910-7. PubMed ID: 17102158
[TBL] [Abstract][Full Text] [Related]
14. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
Sheffield CA; Kane MP; Busch RS
Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
[TBL] [Abstract][Full Text] [Related]
15. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
[TBL] [Abstract][Full Text] [Related]
16. Family Weight School treatment: 1-year results in obese adolescents.
Nowicka P; Höglund P; Pietrobelli A; Lissau I; Flodmark CE
Int J Pediatr Obes; 2008; 3(3):141-7. PubMed ID: 18608623
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of a home-based exercise program for overweight and obese patients with advanced heart failure.
Evangelista LS; Doering LV; Lennie T; Moser DK; Hamilton MA; Fonarow GC; Dracup K
Am J Cardiol; 2006 Mar; 97(6):886-90. PubMed ID: 16516595
[TBL] [Abstract][Full Text] [Related]
18. Effect of a community-based weight management program on weight loss and cardiovascular disease risk factors.
Graffagnino CL; Falko JM; La Londe M; Schaumburg J; Hyek MF; Shaffer LE; Snow R; Caulin-Glaser T
Obesity (Silver Spring); 2006 Feb; 14(2):280-8. PubMed ID: 16571854
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.
Gadde KM; Yonish GM; Wagner HR; Foust MS; Allison DB
Int J Obes (Lond); 2006 Jul; 30(7):1138-42. PubMed ID: 16418753
[TBL] [Abstract][Full Text] [Related]
20. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
